Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P1101 (Ropeginterferon alfa-2b) in Chinese PV Patients Intolerant or Resistant to Hydroxyurea
NCT05485948Phase 2Active, not recruiting
- Sponsor
- PharmaEssentia
- Start
- Oct 2021
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ropeginterferon alfa-2b in polycythemia vera (PV), sponsored by PharmaEssentia. Started Oct 2021; status: active, not recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT05485948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485948.